JMA Journal

Table 1. Summary of the Characteristics of the Eligibility Studies.

From: The Efficacy and Safety of Somatostatin Analog after Axillary Node Dissection in Breast Cancer: A Systematic Review and Meta-analysis

Authors [reference]	Year	Country	Subjects (intervention/ control)	Age (years) (intervention/ control)	Surgery type	Intervention (somatostatin analog)	Control	Published or unpublished
Carcoforo ⁽¹⁷⁾	2003	Italy	125/136	63/63	Mastectomy	Octreotide	Standard treatment	Published
Mahmoud ⁽¹⁸⁾	2007	Egypt	30/20	47/49	Mastectomy	Octreotide	Standard treatment	Published
Chemi SpA ⁽¹⁹⁾	2012	Italy	86/28	56/54	Mastectomy	Octreotide	Placebo	Unpublished
Gauthier ⁽²⁰⁾	2012	France	72/73	56/59	Mastectomy	Lanreotide	Placebo	Published
Chéreau ⁽²¹⁾	2016	France	42/48	55/52	Mastectomy	Pasireotide	Placebo	Unpublished
Chemi SpA ⁽²²⁾	2020	Italy	24/24	NR/NR	Mastectomy	Octreotide	Placebo	Published
Prajapati ⁽²³⁾	2021	India	15/15	48/45	Mastectomy	Octreotide	Standard treatment	Published

» Back to article page

Table 2 Quality scores of the Eligibility Studies for the Drained Fluid Volume.

From: The Efficacy and Safety of Somatostatin Analog after Axillary Node Dissection in Breast Cancer: A Systematic Review and Meta-analysis

Authors [reference]	Risk of bias 2 tool assessment
Authors [reference]	Bias arising from the randomization process	Bias due to deviations from intended interventions	Bias due to missing outcome data	Bias in the measurement of the outcome	Bias in the selection of the reported results	Overall risk of bias
Carcoforo ⁽¹⁷⁾	Some concerns	Low	Low	Low	Some concerns	Some concerns
Mahmoud ⁽¹⁸⁾	Some concerns	Low	Low	Some concerns	Some concerns	Some concerns
Gauthier ⁽²⁰⁾	Some concerns	Low	Low	Low	Some concerns	Some concerns
Chéreau ⁽²¹⁾	Low	Low	Low	Low	Low	Low
Prajapati ⁽²³⁾	Low	Low	Low	Low	Low	Low

» Back to article page

Table 3. Summary of Findings.

From: The Efficacy and Safety of Somatostatin Analog after Axillary Node Dissection in Breast Cancer: A Systematic Review and Meta-analysis

The efficacy and safety of somatostatin analog after axillary node dissection
Patient or population: Adults with breast cancer with axillary lymph node metastasis; Setting: Inpatients; Intervention: Somatostatin analog; Comparison: Placebo or standard treatment
Outcomes	Anticipated absolute effects^* (95% CI)		Relative effect (95% CI)	Patients (studies)	Certainty of the evidence (GRADE)	Comments
Outcomes	Risk with control	Risk with somatostatin analog	Relative effect (95% CI)	Patients (studies)	Certainty of the evidence (GRADE)	Comments
Drained fluid volume	Median volume of drained fluid = 145 mL	MD −22.1 mL (−42.1 to −2.1)	-	576 (5 RCTs)	Low^a,b	Somatostatin analog reduced the drained fluid volume
Drainage duration	Median duration of drainage = 4.5 days	MD −0.48 days (−1.43 to 0.46)	-	685 (6 RCTs)	Low^a,b	Somatostatin analog resulted in little to no difference in the drainage duration
Seroma	459 per 1000	418 per 1000 (280 to 615)	RR 0.91 (0.61 to 1.34)	311 (4 RCTs)	Low^a,b	Somatostatin analog resulted in little to no difference in seroma
Hematoma	8 per 1000	4 per 1000 (1 to 28)	RR 0.53 (0.08 to 3.53)	253 (3 RCTs)	Low^b,c	Somatostatin analog resulted in little to no difference in hematoma
Surgical site infection	31 per 1000	19 per 1000 (8 to 44)	RR 0.62 (0.27 to 1.41)	598 (5 RCTs)	Low^b,c	Somatostatin analog resulted in little to no difference in surgical site infection
Length of hospitalization	Median length of hospitalization = 5 days	MD −0.79 SD (−1.30 to −0.27)	-	526 (4 RCTs)	Low^a,b	Somatostatin analog reduced the length of hospitalization

» Back to article page

PAGE TOP